Monitoring of cardiotoxicity during immunotherapy with Herceptin using simultaneous continuous wave Doppler depending on N-terminal pro-brain natriuretic peptide [1]

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 7, Issue 1, 2007, Pages 88-89

  Knobloch, K ^a   Tepe, J ^a   Lichtinghagen, R ^a   Luck, H J ^a   Vogt, P M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; TRASTUZUMAB;

AMINO TERMINAL SEQUENCE; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; DOPPLER ECHOGRAPHY; ECHOCARDIOGRAPHY; HEART DISEASE; HUMAN; IMMUNOTHERAPY; LETTER;

EID: 33847410251     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.7-1-88     Document Type: Letter

References (4)

1. Hudis C, Seidman A, Paton V et al. Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials. Breast Cancer Res Treat 1998;50:232.
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer overexpresses HER2. N Engl J Med 2001;344:783-92.
3. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002;95:1592-600.
4. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.